Perspective Therapeutics (NYSEAMERICAN:CATX) Price Target Cut to $14.00 by Analysts at Royal Bank Of Canada

Perspective Therapeutics (NYSEAMERICAN:CATX) had its price objective lowered by Royal Bank Of Canada from $18.00 to $14.00 in a research report sent to investors on Tuesday morning,Benzinga reports. Royal Bank Of Canada currently has an outperform rating on the stock.

Other equities research analysts have also recently issued reports about the stock. Truist Financial assumed coverage on shares of Perspective Therapeutics in a research report on Monday, November 24th. They issued a “buy” rating and a $12.00 price objective for the company. BTIG Research reaffirmed a “buy” rating and set a $14.00 target price on shares of Perspective Therapeutics in a research report on Tuesday. Wedbush reiterated an “outperform” rating and issued a $11.00 price target on shares of Perspective Therapeutics in a report on Friday, January 30th. UBS Group reissued a “buy” rating and issued a $7.00 price objective (down from $18.00) on shares of Perspective Therapeutics in a research note on Friday, November 21st. Finally, B. Riley Financial reduced their price objective on Perspective Therapeutics from $12.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. One research analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the company’s stock. According to data from MarketBeat.com, Perspective Therapeutics currently has a consensus rating of “Buy” and an average price target of $12.13.

Perspective Therapeutics Stock Down 5.2%

NYSEAMERICAN:CATX opened at $4.95 on Tuesday. Perspective Therapeutics has a twelve month low of $1.60 and a twelve month high of $6.16. The company has a current ratio of 8.66, a quick ratio of 8.66 and a debt-to-equity ratio of 0.01. The stock has a fifty day simple moving average of $4.26 and a 200-day simple moving average of $3.42.

Perspective Therapeutics (NYSEAMERICAN:CATX) last posted its quarterly earnings results on Monday, March 16th. The company reported ($0.51) EPS for the quarter. The company had revenue of $0.04 million during the quarter. Perspective Therapeutics had a negative return on equity of 40.03% and a negative net margin of 9,841.86%. Research analysts expect that Perspective Therapeutics will post -0.88 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its stake in Perspective Therapeutics by 5.0% during the 3rd quarter. Vanguard Group Inc. now owns 3,437,865 shares of the company’s stock worth $11,792,000 after buying an additional 163,532 shares during the period. Avidity Partners Management LP boosted its position in Perspective Therapeutics by 7.2% in the 4th quarter. Avidity Partners Management LP now owns 3,210,733 shares of the company’s stock valued at $8,830,000 after buying an additional 216,700 shares during the period. Geode Capital Management LLC grew its stake in shares of Perspective Therapeutics by 15.8% in the second quarter. Geode Capital Management LLC now owns 1,382,814 shares of the company’s stock worth $4,758,000 after acquiring an additional 188,887 shares in the last quarter. Opaleye Management Inc. acquired a new position in shares of Perspective Therapeutics in the fourth quarter worth $3,257,000. Finally, State Street Corp increased its position in shares of Perspective Therapeutics by 3.3% during the fourth quarter. State Street Corp now owns 1,141,247 shares of the company’s stock worth $3,138,000 after acquiring an additional 36,543 shares during the period. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics News Summary

Here are the key news stories impacting Perspective Therapeutics this week:

• Positive Sentiment: Updated clinical data for the company’s lead radiopharmaceutical, [212Pb]VMT‑α‑NET, was accepted for a poster at the AACR Annual Meeting (April 20). The program’s interim safety and preliminary efficacy signals — no dose‑limiting toxicities reported and 76% of patients in the reported cohort without progression — increase visibility and could support future upside if further data confirm efficacy. Read More.
• Positive Sentiment: BTIG Research reaffirmed a “Buy” rating and a $14 price target, signaling continued institutional confidence from at least one research shop — a supportive note for momentum traders and long-term holders. Read More.
• Positive Sentiment: Recent insider purchases (reported in Quiver) show company insiders adding shares, which can be interpreted as management confidence in the business and pipeline. Read More.
• Neutral Sentiment: RBC cut its price target from $18 to $14 but maintained an “Outperform” rating — a mixed signal (lower upside expectation but continued analyst support). This may temper upside while keeping institutional interest. Read More.
• Negative Sentiment: Recent financial results and the latest quarterly report show continuing operating losses (reported EPS of -$0.51 for the quarter and minimal revenue), a very negative net margin, and elevated cash‑burn risk — factors that increase financing and execution risk until positive clinical proof or clearer commercialization path emerges. Read More.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.